Influenza Vaccine Market Worth USD 7.60 Billion at 6.9% CAGR by 2027

Pune, Sept. 11, 2020 -- The global influenza vaccine market is expected to gain momentum by reaching USD 7.60 billion by 2027 owing to the increasing prevalence of chronic disease and the growing efforts in R&D activities by major companies to develop innovative and effective influenza vaccine treatment during the forecast period.

This information is published by Fortune Business Insights, in its latest report, titled, “Influenza Vaccine Market Size, Share & COVID-19 Impact Analysis, By Type (Inactivated and Live Attenuated), By Valency (Quadrivalent and Trivalent), By Age Group (Pediatric and Adults), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers and Others) and Geography Forecast, 2020-2027.” The report further observes that the market stood at USD 4.45 billion in 2019 and is likely to exhibit a CAGR of 6.9% between 2020 and 2027.

Influenza, also known as flu, is generally a respiratory illness that occurs due to a viral infection. It is highly contagious and mainly spreads through respiratory droplets. In addition to this, it can pass from one person to another through physical contact and while talking. Owing to their serious implications on health, global healthcare organizations such as the Centers for Disease Control and Prevention (CDC) have recommended certain influenza vaccines such as baloxavir marboxil (Xofluza) to treat the symptoms in patients.

Request a Sample Copy of the Research Report:

What does the Report Include?

The market report includes a detailed assessment of various drivers and restraints, opportunities, and challenges that the market will face during the projected horizon. Additionally, the report provides comprehensive insights into the regional developments of the market, affecting its growth during the forecast period. It includes information sourced from the advice of expert professionals from the industry by our research analysts using several research methodologies. The competitive landscape offers further detailed insights into strategies such as product launches, partnership, merger and acquisition, and collaborations adopted by the companies to maintain market stronghold between 2020 and 2027.

Increasing Demand for Flu Vaccine amid COVID-19 to Aid Growth

The increasing focus on R&D activities to develop a vaccine to contain the widespread effect of the novel coronavirus is driving the demand for immunization across the globe. The COVID-19 pandemic has brought unprecedented changes in the healthcare industry. An increasing demand for the seasonal influenza vaccine to ensure better protection against the deadly pandemic is anticipated to favor the market growth in the near future.


Increasing Prevalence of Influenza to Favor Growth

According to the World Health Organization (WHO), seasonal influenza has serious implications for health globally. It is estimated that around 1 billion people are affected by it every year. The increasing prevalence of chronic disease is propelling the manufacturers to develop innovative influenza vaccines. The increasing geriatric population globally is further anticipated to favor the global flu vaccine market during the forecast period. The global healthcare organizations have recommended several licensed vaccines that are being adopted largely to prevent chronic diseases that are propelling the companies to invest in developing innovative vaccines globally. This is expected to bode well for the market growth in the forthcoming years.


Pediatric Segment to Remain at the Forefront; Increasing Adoption of Immunization Strategy to Spur Demand

The pediatric segment, based on age group, is expected to showcase an exponential growth. This is attributable to the increasing rate of influenza amongst infants and the younger population that is driving the demand for an efficient influenza vaccine.


Presence of Established Companies in North America to Surge Demand

Among all the regions, North America is expected to hold the highest position in the global flu vaccine market. This dominance is attributable to the presence of established companies such as Emergent BioSolutions, Inc. that are increasing their focus on developing advanced influenza vaccines for therapeutic purposes in countries such as the U.S. The region stood at USD 2.18 billion in 2019.

The market in Asia-Pacific is expected to showcase a significant growth in the forthcoming years. This is ascribable to factors such as the increasing geriatric population and the supportive government initiative to promote this vaccine between 2020 and 2027.


Abbott Announces Launch of New Quadrivalent Vaccine to Strengthen its Product Portfolio

The global influenza vaccine market is consolidated with the presence of dominating players such as Sanofi that are focusing on upgrading their technology to manufacture advanced flu vaccine and consolidate their positions. The other key players are adopting strategies such as the introduction of new products, collaboration, and partnerships to strengthen their product portfolios and maintain their presence in the global marketplace. For instance, in February 2020, Abbott announced the launch of a new inactivated quadrivalent vaccine for influenza treatment. According to the company, the vaccine received approval for adoption in children below 3 years in India.

Industry Development:

August 2020 – AstraZeneca announced its collaboration with the leading healthcare industry players such as Sanofi, Seqirus, and GlaxoSmithKline to fast-track the manufacturing of its FluMist vaccine to treat influenza and boost its sales for the period, 2020-21.

List of the Companies Operating in the Influenza Vaccine Market:

  • GlaxoSmithKline plc. (U.K, Europe)
  • Sanofi S.A (France, Europe)
  • AstraZeneca (Cambridge, United Kingdom)
  • Seqirus (Maidenhead, UK)
  • BioDiem (South Melbourne Victoria)
  • Emergent BioSolutions Inc. (Maryland, United States)
  • F. Hoffmann-La Roche Ltd (Basel, Switzerland)
  • Sinovac Biotech Ltd (China)
  • Other Prominent Players

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245

Related Posts

Subscribe Our Newsletter